AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01300364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Reboxetine
Description: 8mg/day.
Study NCT01300364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram (SSRI)
Description: 30mg/day
Study NCT01300364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: citalopram (SSRI)
Description: 30mg/day
Study NCT01932658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
Study NCT00045487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-774
Description: OSI-774 is an orally active, potent, selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
Study NCT04248062 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey: 38 preselected patient and parent reported outcomes; rating scale: 9 point likert scale (1=not at all important - 9=very important)
Study NCT02067741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR1447
Description: 400 mg, corresponding to two 4 g stick packs applications twice daily
Study NCT00979680 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose radiotherapy
Description: Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.
Study NCT00979680 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemo-radiotherapy
Description: Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
Study NCT00712426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Monohydrate
Description: Up to 40 grams daily, powder form creatine monohydrate, taken for the trial duration
Study NCT00712426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
Study NCT00435396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A
Description: Intramuscular injection, 3 doses
Study NCT02637375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Study NCT02637375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02637375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02637375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02232490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepcortespenlisimut-L
Description: hepcortespenlisimut-L (V5) is given in experimental arm
Study NCT02232490 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01947634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ResMed Apnea Link plus
Description: Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
Study NCT01193036 — intervention group
Intervention type: BEHAVIORAL
Intervention: Part 1: Interview + Questionnaires
Description: Questionnaires to be completed immediately after interview, which will take approximately 15 minutes.
Study NCT01193036 — intervention group
Intervention type: BEHAVIORAL
Intervention: Part 2: Multiple Questionnaires
Description: Questionnaires to be repeated about every 2 weeks for 1 year.
Study NCT00944749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: h-ATG (ATGAM )
Study NCT00944749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Gengraf )
Study NCT00921726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
Study NCT01515930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Computer-Delivered Motivational Intervention
Description: Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding monitoring diabetes care.
Study NCT01515930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent & Child Computer-Delivered Motivational Intervention
Description: Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring \& resolving ambivalence, with a strong evidence for improving adolescent \& adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation \& goals they set regarding diabetes care.
Study NCT01515930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Delivered Information
Description: Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
Study NCT01938404 — intervention group
Intervention type: BIOLOGICAL
Intervention: Octaplas
Description: Octoplas infusion solution for IV administration
Study NCT01938404 — intervention group
Intervention type: DRUG
Intervention: Standard Plasma
Description: Plasma given as replacement fluid
Study NCT02824718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: human recombinant parathormone
Study NCT02824718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazide
Description: Diuretic
Study NCT02824718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium sparing diuretic
Description: Diuretic
Study NCT02824718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol
Description: Belongs to the class of vitamin D and analogues
Study NCT03137927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine GamLPV
Description: live intranasal vaccine for whooping cough prevention
Study NCT03137927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02476409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolvaptan
Description: Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
Study NCT04131543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 20 MG
Description: Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
Study NCT04131543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 MG
Description: Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
Study NCT04131543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 MG
Description: Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
Study NCT02253030 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Study NCT00714493 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Infliximab
Description: 3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
Study NCT04650152 — intervention group
Intervention type: DRUG
Intervention: Tricor (fenofibrate), 145 mg, film-coated tablet
Description: Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
Study NCT04046796 — intervention group
Intervention type: GENETIC
Intervention: NGS Diagnostic
Description: Blood take for genetic diagnostic.
Study NCT02058212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ascorbate 1000mg, vitamin E 400, zinc and selenium
Description: anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
Study NCT02058212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ascorbate 1000mg, vitamin E 400, zinc and selenium
Description: anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
Study NCT00368901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
Study NCT05367479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Peri-operative, intravenous antibiotic for surgical site infection
Study NCT00793780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone 25mg
Description: Naltrexone 25mg caplets taken orally once a day for 8 weeks
Study NCT00793780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo caplet (inactive substance) taken orally once a day for 8 weeks
Study NCT05288036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Rehabilitation group
Description: The PNF technique was performed in the supine position with the hip joints of the patients in 30° flexion and the lower extremities in semi-flexion. The application was performed in 2 different diagonal and 4 different patterns (flexion-abduction-external rotation/extension-abduction-internal rotation, and flexion-adduction-external rotation/extension-abduction-internal rotation) of the upper extremity. When starting the exercise, the muscles were first brought to their longest position and the patient was asked to move in the direction of the pattern with resistance (concentric contraction) and to maintain this position for 6 seconds at the end of the pattern (isometric contraction). Then, while the therapist was taking the patient's arm to the starting position, the patient was asked to prevent movement (eccentric contraction). All of these moves counted as one repetition. 3 sets of 8-12 repetitions were performed for each pattern.
Study NCT05288036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise Group
Description: Strengthening exercises targeting the upper extremity main muscles were applied to the PRE group with progressive resistance. Dumbbells and sandbags were used as resistance equipment. resistance intensity; 50-80% of a repetition maximum (RM) was determined according to the patient's tolerance. The exercises were applied as 8-12 repetitions and 3 sets. A rest period of 60-90 seconds was allowed between each set. After the 4th week of the training, 1 RM was measured again and the resistance density was updated. The 8 strengthening exercises to be applied were created by taking examples from the literature and in accordance with the Guidelines for implementing exercise programs exercise programs for cancer patients. These exercises are: dumbbell fly, triceps extension, biceps curl up, one-arm bent over row, dumbbell sides rise, lifting the arm forward, wrist curl and side lying shoulder internal -external rotation.
Study NCT05288036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The patients in the control group were instructed to continue their usual daily lives (not changing their physical activity levels, diet, drug use, etc.) until the date of re-evaluation after the initial evaluation. Information was given about the upper extremity normal range of motion exercises that they could apply at home, and a brochure was given.
Study NCT03894748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Study NCT03894748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Study NCT00759239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% / Timolol maleate 0.5%
Description: Solution, morning dosing
Study NCT00759239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% / Timolol maleate 0.5%
Description: Solution, evening dosing
Study NCT03040323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason 60.7Mg Powder for Injection
Description: Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
Study NCT03040323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos injected prior to ultrasound-guided biopsy
Study NCT03011190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional regulation
Description: Educate people with difficulty in regulating their emotions and help them acquire skills to do so
Study NCT03011190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotional regulation
Description: Educate people with difficulty in regulating their emotions and help them acquire skills to do so
Study NCT02379195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
Study NCT02379195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
Study NCT02379195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL infusion
Description: The maximum number of expanded TILs are infused over 30-45 min on day 0
Study NCT02379195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
Study NCT02379195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
Study NCT04301661 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: Blood will be collected from participants at defined time points during the study to measure drug levels and assess platelet activity.
Study NCT02476409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for tolvaptan
Study NCT01007396 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1-step tuberculin skin test (TST) and blood sampling
Description: In only new healthcare workers, the 1-step TST and quantiFERON-TB Gold In-Tube test were performed.
Study NCT01408524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: 2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Study NCT01408524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: 2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Study NCT04301661 — intervention group
Intervention type: DRUG
Intervention: Abacavir/lamivudine
Description: Participants who are already taking abacavir/lamivudine as part of standard HIV care will continue taking their therapy.
Study NCT04301661 — intervention group
Intervention type: DRUG
Intervention: Tenofovir alafenamide/emtricitabine
Description: Participants who are already taking tenofovir alafenamide/emtricitabine as part of standard HIV care will continue taking their therapy.
Study NCT05693870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed space maintainer
Description: Appliance bonded with composite resin or/banded and cemented with glass ionomer cement
Study NCT04301661 — intervention group
Intervention type: DRUG
Intervention: Switch
Description: Participants who are planning to switch from abacavir/lamivudine as part of standard HIV care will change therapy to per the discretion of their HIV provider.
Study NCT01628068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial appendage occlusion
Description: Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
Study NCT02051504 — intervention group
Intervention type: PROCEDURE
Intervention: Accelerometry over one week
Description: The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
Study NCT02051504 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
Study NCT01036893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: prucalopride 2 mg oral dosing o.d. for 6 days
Study NCT02582983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
Study NCT01528475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-hospital cooling
Description: Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
Study NCT02059395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mastery based learning
Description: Participants are allowed to follow the course content at their own speed
Study NCT02059395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time based learning
Description: Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
Study NCT02725905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Modal Education (MME)
Description: The MME curriculum focuses on developing weight management counseling (WMC) skills through several components: 1) a web course focused on WMC knowledge and clinical skill competencies; 2) WMC role-play exercises for an opportunity to use an algorithm to practice patient-centered WMC; 3) personal weight management exercises to increase awareness of Assist activities (e.g. daily food monitoring using mobile apps, etc); 4) obesity bias assessments, video, and discussions to modify attitudes of implicit weight bias; 5) a formative web-based encounter to interact with and receive feedback from a standardized patient; and 6) an enhanced clerkship rotation focusing on providing learning to preceptors and allowing students to observe preceptors counseling patients who are overweight or obese.
Study NCT02725905 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Education (TE)
Description: Current curriculum may consist of topics related to biology, population health, or counseling skills. TE also may include sporadic stand-alone lectures or small group discussions conducted separately or as a part of a patient interviewing or behavioral course.
Study NCT02390492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 treatment
Description: 200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous \[14C\]-ipatasertib on Day 1 of study
Study NCT02390492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 treatment
Description: 200-mg/100-mcCi oral \[14C\]-ipatasertib on Day 15 of study
Study NCT01891981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox
Description: Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I.
Study NCT02308293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: 3x30 seconds 'all out' sprints